Pompano Beach, FL, March 13, 2020 — BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”) a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced the buildout of a brand new R&D lab. Situated in the Company’s 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development pipeline for the Company’s growing Contract Development and Manufacturing (CDMO) business. [Read more…]
Vitro Diagnostics’ Potential Stem Cell Therapy for Coronavirus Infection
GOLDEN, CO; February 27, 2020 — Vitro Diagnostics, Inc. (OTCPK:VODG), dba Vitro Biopharma, reports on a potential therapy of Coronavirus (COVID-19) infections by stem cell transplant. While this therapy is not a method to eradicate or cure Coronavirus, there is evidence to support the concept that infected patients may be more likely to combat and survive infection.
First, stem cells resist viral attack by the expression of certain genes known as interferon gamma stimulated genes (ISGs). These are expressed in stem cells prior to their differentiation. (Wu, X, et al, Cell 172: 423, 2018). Hence, stem cells would be expected to survive even if transplanted into a patient with an active Coronavirus infection. [Read more…]
Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease
NEW YORK, March 10, 2020 — Mesoblast Limited (Nasdaq: MESO; ASX:MSB) announced that it plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) in the United States, Australia, China and Europe. The Company is in active discussions with various government and regulatory authorities, medical institutions and pharmaceutical companies to implement these activities. [Read more…]
First Patient Dosed in Phase I Clinical Trial using RoosterBio’s Cellular Starting Materials
Investigational New Drug (IND) Using RoosterBio’s CliniControl™ Products Enters the Clinic by RoosterBio’s Pharmaceutical Customer
RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today a significant milestone in the regenerative medicine field with the dosing of the first patient using its innovative cellular starting materials. The patient has been treated by RoosterBio’s pharmaceutical customer with an Investigational New Drug (IND) that was manufactured using RoosterBio’s CliniControl cell and media systems. [Read more…]
Tessa Therapeutics Receives Latest FDA RMAT Designation for CD30 CAR-T Cell Therapy
On February 27, 2020, Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, announced its investigational CD30-directed autologous CAR-T cell (CD30 CAR-T) therapy was granted a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA. The therapy is intended to treat patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma.
Tessa Therapeutics is now aiming to initiate its pivotal Phase II multi-site trial in the 4th quarter of 2020. [Read more…]
- « Previous Page
- 1
- …
- 68
- 69
- 70
- 71
- 72
- …
- 96
- Next Page »